| Autor: |
P, Wei, Y-J, Huang, X-H, Zuo, Y-G, Zhang, Z-Q, Tao, C-R, Qiu, Q, Zhang, X-J, Yang, Q, Fu |
| Rok vydání: |
2016 |
| Předmět: |
|
| Zdroj: |
European review for medical and pharmacological sciences. 20(7) |
| ISSN: |
2284-0729 |
| Popis: |
To explore clinical effects of Tirofiban treatment on patients with high-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS) after percutaneous coronary intervention (PCI).107 patients with high-risk NSTE-ACS after PCI were selected and were divided into two groups. One group of 56 patients was treated with Tirofiban and a second group of 51 patients was taken as control. The occurrence conditions of creatine kinase-myoglobin (CK-MB), cardiac troponin1 (cTnI) level, hemorrhage incidents and major adverse cardiac events (MACE) incidents after treatments were compared.After 24 h operation, CK-MB and cTnI level in Tirofiban group were both significantly lower than those in control group (p0.05), while the difference of hemorrhage incidents between two groups is of no statistical significance (p0.05); and the differences in overall occurrence rate of MACE incidents and the occurrence rate of angina pectoris after infarct between two groups were statistically significant (p0.05).Tirofiban could improve the blood supply condition of hearts of patients with high-risk NSTE-ACS after emergent PCI, lower the occurrence rate of MACE incidents, and decrease the risk of hemorrhage. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
